Silverback Therapeutics (SBTX) Stock Price, News & Analysis

Company Overview

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $14.10 to $14.51
• 50-Day Range: $12.10 to $15.49
• 52-Week Range: $2.80 to $8.97
• Volume: 588,879 shs
• Average Volume: 337,931 shs
• Market Capitalization: $519.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed this year?

Silverback Therapeutics' stock was trading at $10.55 at the beginning of 2025. Since then, SBTX shares have increased by 36.5% and is now trading at $14.40.
View the best growth stocks for 2025 here.

How were Silverback Therapeutics' earnings last quarter?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.65) EPS for the quarter, hitting the consensus estimate of ($0.65).

When did Silverback Therapeutics IPO?

Silverback Therapeutics (SBTX) raised $126 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silverback Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silverback Therapeutics investors own include Athenex (ATNX), AbbVie (ABBV), Applied Materials (AMAT), JPMorgan Chase & Co. (JPM), Luminar Technologies (LAZR), Lineage Cell Therapeutics (LCTX) and Aviat Networks (AVNW).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 6/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SBTX
• CIK: 1671858
• Web: www.silverbacktx.com
• Phone: 206 456 2900
• Fax: N/A
• Employees: 83
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.62%
• Return on Assets: -28.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 67.87
• Quick Ratio: 67.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.41 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 36,058,000
• Free Float: 23,654,000
• Market Cap: $519.24 million
• Optionable: Not Optionable
• Beta: 0.60